Loading...
XNAS
GOVX
Market cap575kUSD
May 21, Last price  
0.98USD
1D
-5.78%
1Q
-39.88%
Jan 2017
-99.99%
Name

GeoVax Labs Inc

Chart & Performance

D1W1MN
P/E
—
P/S
3.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.35%
Rev. gr., 5y
27.45%
Revenues
4m
0852,905237,0042,910,1703,668,1955,185,2574,899,8852,657,0002,417,550882,956428,081828,9181,075,270963,0001,175,8961,823,000385,00081,00003,954,576
Net income
-25m
L-3.75%
-1,408,534-584,166-4,241,796-3,728,187-3,284,252-2,747,328-2,346,826-2,135,000-2,284,943-2,733,555-2,689,287-3,271,701-2,170,162-2,560,000-2,375,124-2,938,344-18,531,479-14,014,561-25,966,762-24,992,296
CFO
-24.68t
L+98,021,131.65%
-1,426,441-1,327,941-3,265,743-2,367,886-1,425,150-2,007,169-303,621-2,441,247-1,694,592-2,250,107-2,705,263-1,946,119-1,688,464-1,543,026-1,398,497-2,750,570-11,196,420-19,030,208-25,173,639-24,675,511,000,000
Earnings
Aug 04, 2025

Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
URL
https://www.geovax.com/
IPO date
Apr 04, 1994
Employees
14
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,955
 
81
-78.96%
Cost of revenue
29,099
47,390
14,166
Unusual Expense (Income)
NOPBT
(25,144)
(47,390)
(14,085)
NOPBT Margin
Operating Taxes
(7)
Tax Rate
NOPAT
(25,144)
(47,390)
(14,078)
Net income
(24,992)
-3.75%
(25,967)
85.28%
(14,015)
-24.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
21,398
4,062
27,727
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
1,748
Net debt
(5,506,941,000)
(6,453)
(27,613)
Cash flow
Cash from operating activities
(24,675,511,000)
(25,174)
(19,030)
CAPEX
(49)
(134)
Cash from investing activities
(20,653,000)
(49)
(134)
Cash from financing activities
23,750,516,000
4,062
35,353
FCF
(149,998,935)
(45,190)
(16,319)
Balance
Cash
5,506,941,000
6,453
27,613
Long term investments
Excess cash
5,506,940,802
6,453
27,609
Stockholders' equity
(129,356,081,000)
(104,362)
(78,371)
Invested Capital
134,404,616,000
110,125
104,971
ROIC
ROCE
EV
Common stock shares outstanding
5,187
2,540
2,540
Price
Market cap
EV
EBITDA
95,342,856
(47,315)
(14,029)
EV/EBITDA
Interest
21
57
Interest/NOPBT